Search results
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 5 days agoAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2024 Earnings Call Transcript May 2, 2024 Agios...
NHS to provide Pfizer’s Voxelotor to treat sickle cell disease
Pharmaceutical Technology via Yahoo Finance· 5 days agoThe UK's National Health Service (NHS) has announced plans to offer Pfizer's Voxelotor (Oxbryta), a...
Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates
Zacks via Yahoo Finance· 5 days agoAgios (AGIO) reports mixed earnings results for first-quarter 2024. Though sales miss the mark,...
Agios Pharmaceuticals, Inc. to Post Q2 2025 Earnings of ($1.62) Per Share, Zacks Research Forecasts...
ETF DAILY NEWS· 10 hours agoAgios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) – Equities researchers at Zacks Research raised their Q2 2025 earnings per share (EPS) estimates for Agios Pharmaceuticals in a report ...
Zenas adds $200M series C to reach a bucket of key readouts for its lead monoclonal antibody
FierceBiotech· 1 day agoZenas BioPharma has bagged a $200 million series C, extending its cash runway another 18 months...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 2 days agoAgios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present ...
Agios Pharmaceuticals (NASDAQ:AGIO) PT Raised to $33.00
ETF DAILY NEWS· 3 days agoAgios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) had its price target lifted by equities research analysts at The Goldman Sachs Group from $29.00 to $33.00 in a note issued to investors ...
Handelsbanken Fonder AB Purchases 2,900 Shares of Immunovant, Inc. (NASDAQ:IMVT)
ETF DAILY NEWS· 6 days agoHandelsbanken Fonder AB boosted its position in Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 32.6% during the 4th quarter, according to the company in its most recent Form 13F filing with ...
